PNPLA3 and metabolic dysfunction-associated steatotic liver disease: This could in principle allow a better stratification of HCC risk than those allowed by the PNPLA3 I148M variant alone, which was proposed by the EASL-EASD-EASO NAFLD guidelines21, 37.